The test is the first offered for the Sgx Clarity system, a fully automated in vitro diagnostic platform leveraging single-molecule counting technology.
Singulex plans to use the investment to continue to develop its single-molecule counting technology.
The firm also plans to list its cardiac troponin I assay as CE marked and plans to submit data to the FDA for clearance of its Clarity system and assay in 2018.
The automated immunodiagnostics system is based on Singulex's single molecule counting technology.
Singulex's CEO provided an update at the JP Morgan Healthcare conference on the firm's progress in developing its immunodiagnostics platform.
The firm is developing a sepsis and SIRS diagnostic that combines its own molecule counting technology with Thermo Fisher's procalcitonin assay.
The immunoassay firm plans to first develop cardiovascular IVDs on its Clarity instrument, followed by assays in oncology and infectious disease.
Through their arrangement, Singulex has granted Grifols an exclusive license to its single-molecule counting technology for use in blood donor and plasma screening.
Executives from Luminex, Exact Sciences, T2 Biosystems, and Singulex provided updates on their companies' businesses on the final day of the conference.
The deal gives EMD Millipore control of Singulex's single-molecule counting technology for research applications.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.